Do you want to read an article? Please log in or register.
The impact of lung surgery, with or without (neo-)adjuvant therapy, on physical functioning in patients with nonsmall cell lung cancer: a scoping review
Lung Cancer
Related content
RECOMMENDED
COPDLung Cancer
Impact of Triple Inhaler Therapy on COPD Patients with Non-Small Cell Lung Cancer After Radical Surgery: A Single-Centre Retrospective Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med
Bertuccio FR, D'Agnano V, Cordoni S, Tafa M, Novy C, Baio N, Mucaj K, Bortolotto C, Melloni G, Bianco A, Corsico AG, Perrotta F, Stella GM
doi: 10.3390/jcm14010249
RECOMMENDED
Lung Cancer
Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Tasoudis P, Loufopoulos G, Manaki V, Doerr M, Agala CB, Long JM, Haithcock BE
doi: 10.1016/j.lungcan.2024.107929
RECOMMENDED
Lung Cancer
Association of Immune-Related Adverse Events With Efficacy in Consolidation Nivolumab Plus Ipilimumab or Nivolumab Alone After Chemoradiation in Patients With Unresectable Stage III Nonsmall Cell Lung Cancer: An Exploratory Analysis From the Big 10 Cancer Research Consortium Study BTCRC LUN 16-081
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wei CX, Althouse SK, Mamdani H, Hanna NH, Durm GA
doi: 10.1016/j.cllc.2024.12.007
RECOMMENDED
Lung Cancer
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A
doi: 10.1016/j.lungcan.2024.108051
Lung Cancer
Conversion Surgery for Initially Unresectable Stage Ⅲ Nonsmall Cell Lung Cancer After Induction Treatment of Immunochemotherapy: A Multicenter Study
Clin Lung Cancer
Wang M, Wang X, Yang R, Geng M, Zhang S, Yang Z, Huang Q, Wang S, Xu S, Jiang K, Liao Y
doi: 10.1016/j.cllc.2024.11.005
RECOMMENDED
Lung Cancer
Stage-Specific Guideline Concordant Treatment Impacts on Survival in Nonsmall Cell Lung Cancer: A Novel Quality Indicator
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Tissera S, Billah B, Brand M, Karim MN, Antippa P, Blum R, Caldecott M, Conron M, Faisal W, Harden S, Olesen I, Parente P, Richardson G, Samuel E, See K, Underhill C, Wright G, Zalcberg J, Stirling RG
doi: 10.1016/j.cllc.2024.08.012
RECOMMENDED
Lung Cancer
Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Kakiuchi Y, Saruwatari K, Murotani K, Tokito T, Iriki T, Iwakawa J, Sakata Y, Shingu N, Saeki S, Inaba M, Takaki A, Misono S, Suetsugu T, Azuma K, Mizuno K, Sakagami T
doi: 10.1016/j.cllc.2024.07.001
RECOMMENDED
Lung Cancer
Completion Rates for Patients Undergoing Concurrent Chemoradiotherapy for Stage III Nonsmall Cell Lung Cancer and its Importance in the Era of Consolidation Immunotherapy: A Cohort Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Wallace ND, Xie J, Alexander M, Ball D, Hegi-Johnson F, Plumridge N, Siva S, Shaw M, Harden S, John T, Solomon B, Irving L, Duffy M, Officer A, MacManus M
doi: 10.1016/j.cllc.2025.02.010
RECOMMENDED
Lung Cancer
The PESGA Trial: A Prospective, Open-Label, Single-Arm, Phase II Study to Evaluate First Line Therapy for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients, Treated by Induction Carboplatin/Etoposide/Pembrolizumab Followed by Maintenance of Pembrolizumab/ Sacituzumab Govitecan
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Roisman LC, Mann S, Basel A, Marei R, Krayim B, Kornev G, Asna N, Peled N
doi: 10.1016/j.cllc.2025.02.002